** Medical device maker GeneDx's shares WGS.O surge 19.3% to $91.1 premarket
** Co posts Q4 revenue of $95.3 mln, beating analyst est of $82.23 mln as per data compiled by LSEG
** Co forecasts 2025 revenue in the range of $350 mln to $360 mln, higher than analysts' expectations of $338.8 mln
** WGS makes medical devices used to diagnose rare genetic disorders, epilepsy and autism
** Co reports adj Q4 net income of $16.8 mln vs analyst est of $2.9 mln
** Stock had risen 17.3x in the last 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。